Taiho Pharma Licenses PI3Kα Inhibitor Risovalisib (CYH33) to Haihe Biopharma
Taiho Pharmaceutical Grants Exclusive Rights for PI3Kα Inhibitor Risovalisib (CYH33) to Haihe Biopharma Taiho Pharmaceutical Co., Ltd. (“Taiho”) and Haihe Biopharma Co., Ltd. (“Haihe”) today announced the signing of an…
argenx to Showcase Immunology Advances at 2025 AANEM and MGFA Meetings
argenx to Present Comprehensive Immunology Data at 2025 AANEM Annual Meeting and MGFA Scientific Session argenx SE (Euronext & Nasdaq: ARGX), a global immunology company dedicated to improving the lives…
CLARITY Study: 90% Prefer Long-Acting Cabotegravir Over Lenacapavir for HIV
ViiV Healthcare CLARITY Study Shows Cabotegravir Long-Acting Injections More Acceptable and Preferred Over Lenacapavir GSK plc (LSE/NYSE: GSK) announced today that ViiV Healthcare, the global specialist HIV company majority owned…
Zoetis Receives Health Canada Approval for Lenivia® to Treat Osteoarthritis Pain in Dogs
Zoetis Receives Health Canada Approval for Lenivia® to Relieve Osteoarthritis Pain in Dogs Zoetis Inc. today announced that Health Canada has approved Lenivia® (izenivetmab injection) for the treatment of pain…
Regeneron Highlights Oncology Pipeline Progress at ESMO 2025
Regeneron Unveils Key Oncology Pipeline Updates at ESMO 2025, Highlighting Patient-Centric Approaches for Hard-to-Treat Cancers Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updated data from its oncology…
CVS Pharmacy Finalizes Nationwide Acquisition of Rite Aid Assets
CVS Pharmacy Finalizes Nationwide Acquisition of Rite Aid and Bartell Drugs Assets, Expanding Access to Care Across the U.S. CVS Pharmacy, a subsidiary of CVS Health, today announced the successful…
Sanofi Establishes Global Autoimmune Research Hub in Montpellier
Sanofi Establishes Montpellier as the Global Hub for Translational Research in Autoimmune Diseases Sanofi has announced the launch of a Translational Center of Excellence in Montpellier, a first-of-its-kind initiative developed…
Merck Reports Phase 3 Results for Once-Daily HIV Regimen Doravirine/Islatravir (DOR/ISL)
Merck Presents New Phase 3 Data on Investigational Two-Drug HIV Regimen Doravirine/Islatravir (DOR/ISL) Showing Minimal Impact on Weight, Body Composition, and Lipid Levels Merck (NYSE: MRK), known as MSD outside…
Novo Nordisk Acquires Rights to Omeros’ MASP-3 Inhibitor Zaltenibart (OMS906)
Novo Nordisk Acquires Global Rights to Omeros’ MASP-3 Inhibitor Zaltenibart in $2.1 Billion Agreement Novo Nordisk and Omeros Corporation (Nasdaq: OMER) have entered into a definitive asset purchase and license…
Neurological Disorders Cause 11 Million Deaths Annually: Call for Urgent Action
WHO Warns of Global Neurological Health Crisis: Over 11 Million Deaths Annually Demand Urgent Action The World Health Organization (WHO) has issued a stark warning about the growing global burden…
WHO and EU Partner to Digitize Health Systems in Sub-Saharan Africa
WHO and European Union Join Forces to Advance Digital Health Systems Across Sub-Saharan Africa The World Health Organization (WHO) and the European Union (EU) have formally announced a new collaboration…
Medical Product Alert 5/2025: Contaminated Oral Liquid Medicines
WHO Medical Product Alert N°5/2025: Identification of Substandard (Contaminated) Oral Liquid Medicines in the South-East Asia Region The World Health Organization (WHO) has issued Medical Product Alert N°5/2025 concerning the…